ReviewJournal of endocrinological investigation2025
GDF15: An emerging disease target and biomarker of metabolic diseases.
Review in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial.Biomedicines · 2026Article
- Association of elevated circulating GDF15 and risk in acute retinal artery occlusion.Frontiers in neurology · 2026Article
- Unveiling GDF-15: a new frontier in combating diabetic osteoporosis.Frontiers in medicine · 2026Review
- The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what's different?Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeGrowth differentiation factor 15 (GDF15), a member of the transforming growth factor-β (TGF-β) superfamily, has garnered increasing attention for its involvement in metabolic regulation. This review aims to provide a comprehensive overview of the secretion mechanisms and functional roles of GDF15 in metabolic diseases (MD), with the goal of informing future clinical diagnostics, guiding biomarker discovery, and advancing personalized treatment strategies.
methodsThis review synthesizes findings from both experimental and clinical studies that investigate the physiological expression, regulatory mechanisms, and systemic actions of GDF15. Particular focus is placed on the GDF15-GFRAL-RET signaling axis and its influence on glucose and lipid metabolism, appetite regulation, and energy homeostasis across key metabolic organs and systems.
resultsNumerous studies have established a robust correlation between serum GDF15 concentrations and a spectrum of MD. The GDF15-GFRAL-RET signaling pathway is responsible for modulating glucose and lipid metabolism, suppressing appetite, and maintaining energy homeostasis by integrating the actions of various tissue systems, such as the liver, adipose tissue, muscle, the central nervous system, and the peripheral sympathetic nervous system. Additionally, these regulatory effects are largely independent of appetite-regulating hormones such as leptin and glucagon-like peptide-1 (GLP-1), and they may exhibit coordinated effects.
conclusionGDF15 plays a key role in metabolic regulation and shows strong potential as a diagnostic biomarker and therapeutic target for MD. Continued research is needed to support its clinical application and guide the development of personalized treatment strategies.
Indexed as
Identifiers
40569532What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.